Viking Therapeutics (NASDAQ:VKTX) PT Set at $28.00 by HC Wainwright

Share on StockTwits

Viking Therapeutics (NASDAQ:VKTX) has been given a $28.00 price target by stock analysts at HC Wainwright in a note issued to investors on Tuesday, September 18th, Marketbeat.com reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 93.64% from the company’s current price.

Other analysts have also recently issued research reports about the company. ValuEngine raised Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 23rd. Raymond James began coverage on Viking Therapeutics in a research report on Thursday, June 28th. They issued an “outperform” rating and a $15.00 price objective for the company. Maxim Group reissued a “buy” rating and issued a $14.00 price objective (up previously from $8.00) on shares of Viking Therapeutics in a research report on Thursday, May 31st. Roth Capital raised their target price on Viking Therapeutics from $7.50 to $13.00 and gave the stock a “buy” rating in a research note on Friday, June 1st. Finally, SunTrust Banks began coverage on Viking Therapeutics in a research note on Friday, July 20th. They issued a “buy” rating and a $14.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $28.17.

NASDAQ:VKTX traded up $0.59 during midday trading on Tuesday, hitting $14.46. The stock had a trading volume of 3,679,927 shares, compared to its average volume of 2,872,746. Viking Therapeutics has a one year low of $2.00 and a one year high of $24.00. The stock has a market cap of $1.06 billion, a P/E ratio of -18.30 and a beta of 2.81.

Viking Therapeutics (NASDAQ:VKTX) last announced its earnings results on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, sell-side analysts anticipate that Viking Therapeutics will post -0.44 EPS for the current fiscal year.

In other Viking Therapeutics news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of Viking Therapeutics stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $19.15, for a total transaction of $5,034,171.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.90% of the company’s stock.

Several large investors have recently bought and sold shares of VKTX. Janney Montgomery Scott LLC acquired a new stake in shares of Viking Therapeutics during the 2nd quarter valued at about $114,000. Strs Ohio acquired a new stake in Viking Therapeutics in the 2nd quarter worth about $120,000. Cubist Systematic Strategies LLC acquired a new stake in Viking Therapeutics in the 2nd quarter worth about $129,000. State Board of Administration of Florida Retirement System acquired a new stake in Viking Therapeutics in the 2nd quarter worth about $144,000. Finally, Metropolitan Life Insurance Co. NY acquired a new stake in Viking Therapeutics in the 2nd quarter worth about $145,000. Hedge funds and other institutional investors own 53.22% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Read More: Return on Equity (ROE)

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.